论文部分内容阅读
目的:研究骨肉瘤中HER2基因的表达与临床预后的关系。方法:对82例骨肉瘤患者的临床病理资料进行回顾性研究,应用HER2单克隆抗体对组织切片进行免疫组织化学染色,并将上述资料与患者的预后进行分析。结果:骨肉瘤患者HER2表达与患者预后相关(P<0.05),HER2高表达的骨肉瘤患者预后较差。结论:HER2检测是骨肉瘤预后判断的一项有价值的指标;同时,HER2为骨肉瘤的治疗提供一种可能的生物靶点。
Objective: To study the relationship between HER2 gene expression and clinical prognosis in osteosarcoma. Methods: The clinical and pathological data of 82 patients with osteosarcoma were retrospectively studied. Immunohistochemical staining of the tissue sections with HER2 monoclonal antibody was performed. The above data and the prognosis of the patients were analyzed. Results: The expression of HER2 in patients with osteosarcoma correlated with the prognosis of patients (P <0.05). The patients with high expression of HER2 had poor prognosis. Conclusion: The HER2 test is a valuable indicator of the prognosis of osteosarcoma. Meanwhile, HER2 may provide a potential biological target for the treatment of osteosarcoma.